Robert Parkinson - Baxter

Robert Parkinson - Baxter
Total Compensation: $14.1 million

Details: Parkinson rebounded from his 2010 pay cut, which brought him from 2009's $14.4 million down to $11.5 million as the company faced declining revenues and production woes. Now, however, he's back to a healthy $14.1 million, as he pulled in about $1 million more in stock and option awards last year and saw his non-equity incentive plan increase by nearly $2 million. The raise pushed him just ahead of Allergan's ($AGN) David Pyott, who missed this year's top 10 by a paltry (for a pharma CEO) $80,000.

Of late, Baxter has seen positive returns from its plasma-based immune disorder treatments, boasting a 3.2% year-over-year increase in income last quarter, leading to a planned $1 billion investment to construct a drug plant in Atlanta, which is projected to employ about 1,500 people, the company said. There have been a few snags, however, namely for the hopeful big seller HyQ. Baxter projected the drug to get approval this year and bring in up to $200 million by 2014, but the FDA has requested more information on the immunotherapy treatment, delaying the company's progress.

Robert Parkinson - Baxter
Read more on

Suggested Articles

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.